Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
-
Patent number: 10028970Abstract: The invention concerns a cashew apple extract and a composition comprising a cashew apple extract and optionally a carrier, in particular for use for allowing reduction of body weight gain or limitation of increasing body weight, reduction or limitation of fat storage, of fatty liver, of liver triglycerides level, of hypertriglyceridemia, of glycemia level, of insulinemia, of insulin resistance, and/or of one or several factors of metabolic syndrome.Type: GrantFiled: June 7, 2012Date of Patent: July 24, 2018Assignee: NATUREXInventors: Nicolas Chapal, Max Reynes, Vickram Beejmohun, Manuel Dornier
-
Patent number: 9981936Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.Type: GrantFiled: June 14, 2017Date of Patent: May 29, 2018Assignee: MEI Pharma, Inc.Inventor: Ofir Moreno
-
Patent number: 9975868Abstract: In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.Type: GrantFiled: May 12, 2017Date of Patent: May 22, 2018Assignee: Emory UniversityInventor: Keqiang Ye
-
Patent number: 9962364Abstract: The purpose of the present invention is to provide a specific wound healing accelerator effective for accelerating healing of wounds, particularly of wounds in the oral cavity, or a composition which includes the wound healing accelerator. This wound healing accelerator including a specific polyphenol is easy to handle and is capable of accelerating would healing even by contact for a short time.Type: GrantFiled: December 25, 2013Date of Patent: May 8, 2018Assignee: A-Z LTD.Inventors: Yoshimi Niwano, Taro Kanno, Keisuke Nakamura, Minoru Kanno
-
Patent number: 9956199Abstract: The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection.Type: GrantFiled: November 17, 2016Date of Patent: May 1, 2018Inventors: Ludwig Aigner, Sébastien Couillard-Despres
-
Patent number: 9901565Abstract: The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.Type: GrantFiled: December 23, 2014Date of Patent: February 27, 2018Assignee: Protectea, Ltd.Inventors: Kunihiro Kaihatsu, Shuichi Mori, Tomo Daidoji, Nobuo Kato, Shinya Miyake
-
Patent number: 9877946Abstract: A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.Type: GrantFiled: December 9, 2016Date of Patent: January 30, 2018Assignees: Research & Business Foundation Sungkyunkwan University, GYEONGGIDO BUSINESS & SCIENCE ACCELERATORInventors: Kye Won Park, Nojoon Song, Suk Chan Lee, Jin-Mo Ku
-
Patent number: 9861610Abstract: The present invention relates to a process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers of the type A and type B, of more than 90% purity as gallic acid equivalent which comprises the steps of removing the organic solvent from the extract to produce the free flowing oleoresin and drying of the residue under optimized conditions to produce a polyphenol and procyanidin Type A & B polymer rich solid which on subsequent extraction with water or with mixture of water and acetone or water and lower alcohol and further evaporation to a solid content of not more than 6% and subsequent chromatographic separation to obtain fractions containing procyanidin type A and B polymers free of coumarins and cinnamaldehyde. The present invention also relates to stable composition comprising cinnamon polyphenol rich powder for delivering maximum bioactivity upon oral administration.Type: GrantFiled: July 31, 2012Date of Patent: January 9, 2018Assignee: AKAY FLAVOURS & AROMATICS PVT LTD.Inventors: Krishnakumar Illathu Madhavamenon, Abin Isaac, Dineshkumar Unnikrishnan, Aswin Koshy Jacob Vaidyan, Balu Paulose Maliakel
-
Patent number: 9855204Abstract: A treatment method including: (a) identifying a subject in need of treatment for androgenic alopecia (AGA), and (b) orally administering a physiologically effective amount of cepharanthine (CEP) to the subject according to a dosage regimen.Type: GrantFiled: December 22, 2016Date of Patent: January 2, 2018Inventor: Moshe Rogosnitzky
-
Patent number: 9848624Abstract: The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular Rubus suavissimus extracts, for masking, reducing or suppressing a bitter, sour and/or astringent taste impression. The invention further relates to orally consumable preparations, comprising at least one bitter, sour and/or astringent-tasting substance and rubusoside or certain rubusoside-containing mixtures, preferably certain Rubus suavissimus extracts, a corresponding method of producing said preparations and a method for reducing or suppressing the bitter, sour and/or astringent effect of a bitter, sour and/or astringent-tasting substance. The invention further relates to certain flavoring compositions that are particularly effective for masking, reducing or suppressing a bitter, sour and/or astringent taste impression.Type: GrantFiled: June 4, 2014Date of Patent: December 26, 2017Assignee: Symrise AGInventors: Jakob Peter Ley, Katharina Reichelt, Thomas Riess, Kathrin Langer, Susanne Paetz
-
Patent number: 9840512Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: GrantFiled: February 20, 2014Date of Patent: December 12, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Linda L. Brockunier, Helen Chen, Harry R. Chobanian, Matthew J. H. Clements, Alejandro Crespo, Duane E. DeMong, Yan Guo, William K. Hagmann, Karen M. Marcantonio, Michael Miller, Barbara Pio, Christopher W. Plummer, Dong Xiao
-
Patent number: 9782364Abstract: Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine376 phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.Type: GrantFiled: August 14, 2016Date of Patent: October 10, 2017Inventor: Franco Cavaleri
-
Patent number: 9775825Abstract: The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.Type: GrantFiled: July 17, 2012Date of Patent: October 3, 2017Assignee: Indus Biotech Private LimitedInventors: Sunil Bhaskaran, Mohan Vishwaraman
-
Patent number: 9763910Abstract: Disclosed is a method of treating a subject having non-small cell lung cancer. The method includes administering to the subject a therapeutically effective amount of a composition and the composition contains 5-demethylnobiletin and docetaxel. Compared with the use of docetaxel alone, the method of combining 5-demethylnobiletin and docetaxel had a 4.4 fold increase in inhibiting the growth of human lung cancer cells, and had a 3.05 fold increase in inhibiting tumor growth in human lung cancer cell-engrafted nude mice.Type: GrantFiled: December 31, 2016Date of Patent: September 19, 2017Assignee: Huanggang Normal UniversityInventor: Shiming Li
-
Patent number: 9750716Abstract: The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders, vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.Type: GrantFiled: March 18, 2016Date of Patent: September 5, 2017Inventor: Wendy Anne Epstein
-
Patent number: 9745279Abstract: The present invention provides a sirtuin activator with an active component composed of black ginger or a black ginger extract, which is easily obtainable, extremely safe, and eaten from old. The present invention further provides a sirtuin activator with an active component of polyalkoxyflavonoid compound represented by general formula (I) and having a sirtuin activation effect that is 10 folds that of resveratrol or higher: wherein, R1 to R7 are each independently a hydrogen atom, a hydroxyl group, or a C1 to C6 lower alkoxy group.Type: GrantFiled: December 27, 2012Date of Patent: August 29, 2017Assignees: TOKIWA PHYTOCHEMICAL CO., LTD.Inventors: Tsutomu Shimada, Jinwei Yang, Yuka Koike
-
Patent number: 9744164Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.Type: GrantFiled: February 26, 2016Date of Patent: August 29, 2017Assignee: Salk Institute for Biological StudiesInventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Patent number: 9724325Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.Type: GrantFiled: September 7, 2016Date of Patent: August 8, 2017Assignee: Humanetics CorporationInventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
-
Patent number: 9717700Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.Type: GrantFiled: November 23, 2015Date of Patent: August 1, 2017Assignee: Syntrix Biosystems Inc.Inventor: John A. Zebala
-
Patent number: 9717701Abstract: Disclosed herein is a composition for oral administration of O-desmethyltramadol that is effective for overcoming resistance to tramadol in patients.Type: GrantFiled: April 6, 2016Date of Patent: August 1, 2017Assignee: Syntrix Biosystems Inc.Inventor: John A. Zebala
-
Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) for use in the treatment of endometriosis
Patent number: 9713603Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of Pro-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.Type: GrantFiled: August 20, 2013Date of Patent: July 25, 2017Assignees: The Hong Kong Polytechnic University, The Chinese University of Hong KongInventors: Tak-Hang Chan, Chi-Chiu Wang -
Patent number: 9707212Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: October 27, 2015Date of Patent: July 18, 2017Assignee: Nivalis Therapeutics, Inc.Inventors: Xicheng Sun, Jian Qiu
-
Patent number: 9701655Abstract: The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence or risk of cancer recurrence.Type: GrantFiled: February 5, 2015Date of Patent: July 11, 2017Assignee: NOVOGEN LIMITEDInventors: Andrew Heaton, David Brown, Graham Kelly
-
Patent number: 9700512Abstract: A method of preparing hesperetin nanoparticles includes dissolving hesperetin in an organic solvent to form a solution; spraying the solution in boiling water while applying ultrasonic energy to form a mixture; and stirring the mixture for at least about 15 minutes at a speed of about 200-800 rpm to obtain the hesperetin nanoparticles.Type: GrantFiled: May 10, 2016Date of Patent: July 11, 2017Assignee: KING SAUD UNIVERSITYInventors: Mai Abdelrahman Elobeid Wagealla, Lulwah Saleh Mohammed Al-Hassan, Manal Ahmed Gasmelseed Awad, Nouf Abdullah Mureet Al-Ghamdi, Promy Virk, Awatif Ahmed Hendi
-
Patent number: 9687469Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.Type: GrantFiled: August 25, 2015Date of Patent: June 27, 2017Assignees: University of Maryland, Baltimore, Educational & Scientific LLCInventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
-
Patent number: 9682047Abstract: Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.Type: GrantFiled: July 7, 2016Date of Patent: June 20, 2017Assignee: Therapeutic Solutions International, Inc.Inventors: Timothy G. Dixon, Gerry B. Berg, Robert F. Graham, Santosh Kesari, Thomas Ichim
-
Patent number: 9682947Abstract: Novel heterocyclo compounds represented by Formula I wherein X, R1, R2, R3, R4, R5, R6 and n are as described herein are provided. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of cancer conditions in mammals including humans, including prostate, colon, bladder, melanoma, liver, breast, cervical, ovarian, esophagi, glialblastoma, pancreatic and lung cancer.Type: GrantFiled: January 29, 2014Date of Patent: June 20, 2017Assignee: New York UniversityInventors: Chuanshu Huang, Qin-Shi Zhao, Zipeng Cao, Jingxia Li, Xu Deng, Chao-Ming Li
-
Patent number: 9682064Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:Type: GrantFiled: July 21, 2016Date of Patent: June 20, 2017Assignees: The Broad Institute, Inc., Massachusetts General HospitalInventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
-
Patent number: 9655940Abstract: The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the COX-2 and 5-LO pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) enzymes, and reducing cox-2 mRNA production. Finally, the present invention includes a method for weight loss and blood glucose control. The methods of this invention are comprised of administering to a host in need thereof an effective amount of the composition of this invention together with a pharmaceutically acceptable carrier.Type: GrantFiled: April 17, 2006Date of Patent: May 23, 2017Assignee: UNIGEN, INC.Inventor: Qi Jia
-
Patent number: 9655878Abstract: The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved.Type: GrantFiled: March 7, 2014Date of Patent: May 23, 2017Assignee: AMOREPACIFIC CORPORATIONInventors: Hee Y. Jeon, Hyun Jung Shin, Dae Bang Seo, Hyeon Ju Yeo, Sang Jun Lee
-
Patent number: 9643976Abstract: The present invention relates to novel solvates of Darunavir of Formula I.Type: GrantFiled: January 11, 2013Date of Patent: May 9, 2017Assignee: Aurobindo Pharma Ltd.Inventors: Anand Gopalkrishna Kamat, Naga Trinadhachari Ganala, Venkata Balaji Boddu, Joseph Prabahar Koilpillai, Sivakumaran Meenaakshisunderam
-
Patent number: 9623004Abstract: A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.Type: GrantFiled: July 30, 2014Date of Patent: April 18, 2017Inventors: Michael D. Kaytor, John L. Zenk, Geoffrey E. Schroeder, Zeljko Vujaskovic, Isabel Lauren Jackson
-
Patent number: 9623003Abstract: Mitigation of long and short-term detrimental effects of exposure to medical imaging ionizing radiation by administration of an effective amount of genistein in the form of a nanosuspension to someone within forty eight hours prior to and/or within twelve hours after exposure to medical imaging ionizing radiation.Type: GrantFiled: April 4, 2013Date of Patent: April 18, 2017Assignee: Humanetics CorporationInventors: Michael D. Kaytor, John L. Zenk
-
Patent number: 9617293Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.Type: GrantFiled: April 7, 2016Date of Patent: April 11, 2017Assignee: Pfizer Inc.Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
-
Patent number: 9585865Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: GrantFiled: December 8, 2014Date of Patent: March 7, 2017Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Holger Zinke
-
Patent number: 9573921Abstract: The present invention relates to compounds of formula (I), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where R1 and R2 are, independently, hydrogen, halogen, C1_3 alkyl or C1-3alkoxy; R3 is phenyl optionally substituted by R4 and R5 which are, independently hydrogen, halogen, C1-3 alkyl, C1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, N,N-diC1-3alkyl-amide, carboC1-3 alkoxy or C1-3alkylsulphone groups; R3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.Type: GrantFiled: September 30, 2013Date of Patent: February 21, 2017Assignee: Polfarmex S.A.Inventors: Piotr Kopczacki, Mieczyslaw Wosko, Jaroslaw Walczak, Krzysztof Walczynski
-
Patent number: 9561224Abstract: A treatment method including: (a) identifying a subject in need of treatment for androgenic alopecia (AGA), and (b) orally administering a physiologically effective amount of cepharanthine (CEP) to the subject according to a dosage regimen.Type: GrantFiled: May 26, 2016Date of Patent: February 7, 2017Inventor: Moshe Rogosnitzky
-
Patent number: 9527860Abstract: The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection.Type: GrantFiled: June 15, 2012Date of Patent: December 27, 2016Inventors: Ludwig Aigner, Eleni Oberbauer-Hofmann, Sébastien Couillard-Despres, Francisco Javier Rivera, Herbert Riepl, Corinna Urmann, Martin Biendl
-
Patent number: 9511104Abstract: The present invention relates to a new approach for treating a cancer or fibrosis, such as hepatocellular carcinoma, or liver fibrosis using an extract from a plant of Graptopetalum sp., Rhodiola sp., or Echeveria sp., and prepared by extracting the plant with dimethyl sulfoxide (DMSO), its fraction or the compound isolated from the extract.Type: GrantFiled: August 13, 2015Date of Patent: December 6, 2016Assignee: NATIONAL YANG-MING UNIVERSITYInventor: Chi-Ying Huang
-
Patent number: 9498487Abstract: The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.Type: GrantFiled: May 19, 2005Date of Patent: November 22, 2016Assignee: EMISPHERE TECHNOLOGIES, INC.Inventors: Puchun Liu, Steven Dinh, Ehud Arbit, Michael M. Goldberg
-
Patent number: 9499509Abstract: A compound of formula (I) as well as pharmaceutical compositions comprising same is provided. An extract of a plant belonging to a species of Populus, the extract comprising this compound is also provided. These can be used as antibacterial for treating bacterial infection.Type: GrantFiled: August 28, 2013Date of Patent: November 22, 2016Assignee: UNIVERSITE DU QUEBEC A CHICOUTIMIInventors: André Pichette, Jean Legault, François Simard
-
Patent number: 9499795Abstract: Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.Type: GrantFiled: August 9, 2013Date of Patent: November 22, 2016Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Patent number: 9486410Abstract: A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.Type: GrantFiled: October 26, 2007Date of Patent: November 8, 2016Assignee: Bend Research, Inc.Inventors: Michael E. Perlman, Ravi M. Shanker, Walter C. Babcock, Dwayne Thomas Friesen, Mark D. Rabenstein, Dan Tod Smithey
-
Patent number: 9486474Abstract: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.Type: GrantFiled: August 7, 2008Date of Patent: November 8, 2016Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: C. Lowell Parsons
-
Patent number: 9474777Abstract: An extract of Graptopetalum paraguayense prepared by a method that includes: extracting a Graptopetalum paraguayense (GP) starting material with an alcoholic solvent to produce an alcoholic extract and a residue; separating the residue from the alcoholic extract; extracting the residue with an aqueous dimethyl sulfoxide (DMSO) solvent to produce a DMSO extract; subjecting the DMSO extract to ultrafiltration using a filter having a selected molecular weight cutoff; drying a fraction retained by the filter to obtain the extract of Graptopetalum paraguayense. Uses of an extract of Graptopetalum paraguayense for the treatment or prevention of liver fibrosis, hepatic cirrhosis, liver cancer, recurrence of liver fibrosis after surgery, or recurrence of liver cancer after surgery.Type: GrantFiled: December 30, 2013Date of Patent: October 25, 2016Assignee: Development Center for BiotechnologyInventors: Yuh-Shan Chung, Ma-Li Siu, Tzung-Hsien Lai, Szu-Chien Yeh
-
Patent number: 9447065Abstract: The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.Type: GrantFiled: October 18, 2012Date of Patent: September 20, 2016Assignee: RaQualia Pharma Inc.Inventors: Yasuhiro Iwata, Kaoru Shimada, Yoshiyuki Okumura, Mayumi Kashino, Hiromitsu Yoshida
-
Patent number: 9439902Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).Type: GrantFiled: November 7, 2014Date of Patent: September 13, 2016Assignee: Pfizer Inc.Inventor: Vincent Mascitti
-
Patent number: 9439901Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).Type: GrantFiled: November 7, 2014Date of Patent: September 13, 2016Assignee: Pfizer Inc.Inventor: Vincent Mascitti
-
Patent number: 9415105Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.Type: GrantFiled: October 30, 2013Date of Patent: August 16, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Michail V. Sitkovsky, Akio Ohta
-
Patent number: 9408824Abstract: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: GrantFiled: March 5, 2014Date of Patent: August 9, 2016Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITEDInventors: Kenneth David Reginald Setchell, Sidney John Cole